ASLAN Pharmaceuticals Limited ASLN

$ 0.6 -14.27%

Annual report 2020
added 08-19-2023

ASLAN Pharmaceuticals Limited Balance Sheet 2011-2024 | ASLN

Annual Balance Sheet ASLAN Pharmaceuticals Limited

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	1.13 M	-4.31 M	-14.9 M	-40.9 M	-43.2 M	-18 M	1.6 M	-	-	-
Long Term Debt	-	15.2 M	17.6 M	14 M	9.67 M	8.31 M	8.26 M	7.18 M	-	-	-
Long Term Debt Current	-	272 K	265 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	15.6 M	18.6 M	14.3 M	9.83 M	8.31 M	61.1 M	29.5 M	-	-	-
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	26.2 M	24 M	22.3 M	15.8 M	12.1 M	63.1 M	31.2 M	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-196 M	-179 M	-132 M	-93.5 M	-48.2 M	-37.7 M	-25.9 M	-	-	-
Total Assets	-	16.1 M	23.3 M	52.9 M	51.3 M	53.5 M	26.5 M	5.82 M	-	-	-
Cash and Cash Equivalents	-	14.3 M	22.2 M	28.9 M	50.6 M	51.7 M	-	-	-	-	-
Book Value	-	-10.2 M	-603 K	30.6 M	35.5 M	41.4 M	-36.6 M	-25.4 M	-	-	-
Total Shareholders Equity	-	-10.2 M	-603 K	30.6 M	35.5 M	41.6 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet ASLAN Pharmaceuticals Limited

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	63.3 K	-	281 K	281 K	352 K	-	491 K	625 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	30.9 M	-	15.6 M	-	15.6 M	18.6 M	18.6 M	-	18.6 M	14.9 M	-	-	14.3 M	-	-	-	9.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	37.2 M	-	20.7 M	-	26.2 M	24.8 M	23 M	-	24 M	19.2 M	-	-	22.3 M	-	-	-	15.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-227 M	-	-208 M	-	-196 M	-190 M	-186 M	-	-179 M	-150 M	-	-	-132 M	-	-	-	-90.3 M	-	-	-	-50.4 M	-	-	-	-41.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	94.5 M	-	96 M	-	16.1 M	13.3 M	15 M	-	23.3 M	32.4 M	-	-	52.9 M	-	-	-	51.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	90.2 M	-	94.1 M	-	14.3 M	12.1 M	13.8 M	-	22.2 M	7.99 M	15.1 M	-	28.9 M	34.8 M	-	-	50.6 M	-	-	-	51.7 M	-	-	-	27.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	57.3 M	-	75.4 M	-	-10.2 M	-11.6 M	-8 M	-	-603 K	13.2 M	-	-	30.6 M	-	-	-	35.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	57.3 M	-	75.4 M	-	-10.2 M	-11.6 M	-8 M	-	-603 K	13.2 M	18.4 M	-	30.6 M	41.8 M	-	-	35.5 M	-	-	-	41.6 M	-	-	-	-37.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency